ES2341170T5 - Péptidos antigénicos derivados de telomerasa - Google Patents

Péptidos antigénicos derivados de telomerasa Download PDF

Info

Publication number
ES2341170T5
ES2341170T5 ES03075681.1T ES03075681T ES2341170T5 ES 2341170 T5 ES2341170 T5 ES 2341170T5 ES 03075681 T ES03075681 T ES 03075681T ES 2341170 T5 ES2341170 T5 ES 2341170T5
Authority
ES
Spain
Prior art keywords
antigenic peptides
derived antigenic
telomerase derived
telomerase
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03075681.1T
Other languages
English (en)
Other versions
ES2341170T3 (es
Inventor
Mona Moller
Jon Amund Eriksen
Gustav Gaudernack
Marianne Klemp Gjertsen
Ingvil Saeterdal
Stein Saeboe-Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gemvax AS
Original Assignee
Gemvax AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2341170(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax AS filed Critical Gemvax AS
Publication of ES2341170T3 publication Critical patent/ES2341170T3/es
Application granted granted Critical
Publication of ES2341170T5 publication Critical patent/ES2341170T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17

Claims (1)

  1. imagen1
    imagen2
ES03075681.1T 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerasa Expired - Lifetime ES2341170T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO983141 1998-07-08
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt
NO19983141 1998-07-08

Publications (2)

Publication Number Publication Date
ES2341170T3 ES2341170T3 (es) 2010-06-16
ES2341170T5 true ES2341170T5 (es) 2014-09-09

Family

ID=19902234

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99928238T Expired - Lifetime ES2200526T5 (es) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerasa.
ES03075681.1T Expired - Lifetime ES2341170T5 (es) 1998-07-08 1999-06-30 Péptidos antigénicos derivados de telomerasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99928238T Expired - Lifetime ES2200526T5 (es) 1998-07-08 1999-06-30 Peptidos antigenicos derivados de telomerasa.

Country Status (20)

Country Link
US (2) US7030211B1 (es)
EP (4) EP2258383B1 (es)
JP (2) JP4618657B2 (es)
CN (1) CN100376290C (es)
AR (2) AR020601A1 (es)
AT (2) ATE247484T1 (es)
AU (1) AU756094B2 (es)
CA (2) CA2336743C (es)
CY (1) CY1109978T1 (es)
CZ (1) CZ303215B6 (es)
DE (2) DE69910580T3 (es)
DK (2) DK1093381T4 (es)
ES (2) ES2200526T5 (es)
HK (1) HK1039068B (es)
HU (1) HU230007B1 (es)
NO (1) NO313834B1 (es)
PL (1) PL203815B1 (es)
PT (2) PT1362597E (es)
TW (1) TWI261617B (es)
WO (1) WO2000002581A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
WO2000061766A2 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
JP2004527449A (ja) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
CA2514288C (en) * 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US20090202499A1 (en) * 2006-01-19 2009-08-13 The Regents Of The University Of California Human Telomerase Reverse Transcriptase Peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
JP5787752B2 (ja) * 2008-06-16 2015-09-30 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 抗腫瘍免疫療法
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
WO2011060104A2 (en) 2009-11-10 2011-05-19 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
LT2536830T (lt) * 2010-02-16 2019-11-11 Ultimovacs Asa Polipeptidai
FR2960542B1 (fr) * 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
EP2707036A4 (en) * 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
KR101873773B1 (ko) 2012-05-11 2018-08-02 주식회사 젬백스앤카엘 류마티즘 관절염 예방 또는 치료 조성물
EP2847213B1 (en) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
KR20150014483A (ko) * 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR101799904B1 (ko) * 2012-07-11 2017-11-22 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN104768967B (zh) * 2012-09-19 2019-02-15 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN107312759A (zh) * 2012-09-19 2017-11-03 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
US9902945B2 (en) * 2012-09-19 2018-02-27 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
US9907838B2 (en) * 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
WO2014178680A1 (ko) * 2013-05-03 2014-11-06 주식회사 카엘젬백스 Hsp 발현 억제 펩티드 및 이를 포함하는 조성물
AU2014275610B2 (en) * 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
EP3011967B1 (en) * 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
KR102224965B1 (ko) * 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
KR101691479B1 (ko) * 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
KR102694658B1 (ko) * 2013-11-22 2024-08-14 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
WO2015088233A1 (ko) * 2013-12-10 2015-06-18 주식회사 카엘젬백스 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
JP6367950B2 (ja) * 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR102373603B1 (ko) * 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN105597078B (zh) * 2014-05-29 2019-01-25 深圳市盛景基因医疗有限公司 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) * 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
KR20180004752A (ko) 2015-05-26 2018-01-12 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
JP6923453B2 (ja) * 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
AU2018206015B2 (en) 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
WO2021212015A2 (en) * 2020-04-17 2021-10-21 Lineage Cell Therapeutics, Inc. Mhc restricted immunogenic telomerase reverse transcriptase -specific peptides, their complex conjugates, and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
DK0880360T3 (da) * 1996-02-12 2003-01-27 Ml Lab Plc Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
JP2000516911A (ja) 1996-03-28 2000-12-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ オプソニン強化細胞、および抗原に対する免疫応答を調節する方法
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
ATE295386T1 (de) * 1996-07-08 2005-05-15 Vivoxid Oy Bioabbaubares material mit hoher schlagzähigkeit
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants

Also Published As

Publication number Publication date
PL345541A1 (en) 2001-12-17
WO2000002581A1 (en) 2000-01-20
JP5491315B2 (ja) 2014-05-14
CN100376290C (zh) 2008-03-26
EP2258383B1 (en) 2016-03-09
ATE458494T1 (de) 2010-03-15
EP1362597B2 (en) 2014-06-25
JP4618657B2 (ja) 2011-01-26
EP2258383A2 (en) 2010-12-08
CZ200137A3 (en) 2001-06-13
US7030211B1 (en) 2006-04-18
JP2002520293A (ja) 2002-07-09
DE69910580T3 (de) 2009-11-26
ATE247484T1 (de) 2003-09-15
HUP0104889A2 (hu) 2002-04-29
EP1362597B1 (en) 2010-02-24
HK1039068B (zh) 2009-02-06
HK1039068A1 (en) 2002-04-12
ES2341170T3 (es) 2010-06-16
CA2748996A1 (en) 2000-01-20
HU230007B1 (en) 2015-04-28
DE69910580D1 (de) 2003-09-25
HUP0104889A3 (en) 2004-04-28
AU756094B2 (en) 2003-01-02
EP1093381B2 (en) 2009-07-22
EP2258383A3 (en) 2011-05-11
TWI261617B (en) 2006-09-11
EP1362597A1 (en) 2003-11-19
US20060106196A1 (en) 2006-05-18
DK1093381T3 (da) 2003-09-08
EP1093381A1 (en) 2001-04-25
CN1313773A (zh) 2001-09-19
AR077576A2 (es) 2011-09-07
DK1093381T4 (da) 2009-09-21
DK1362597T3 (da) 2010-06-14
US7794723B2 (en) 2010-09-14
PL203815B1 (pl) 2009-11-30
EP2316476A3 (en) 2011-09-14
DE69910580T2 (de) 2004-06-24
PT1362597E (pt) 2010-04-14
NO983141L (no) 2000-01-10
JP2010252810A (ja) 2010-11-11
EP2316476A2 (en) 2011-05-04
CA2336743C (en) 2011-10-11
ES2200526T3 (es) 2004-03-01
ES2200526T5 (es) 2009-12-11
DE69942072D1 (de) 2010-04-08
PT1093381E (pt) 2004-01-30
CZ303215B6 (cs) 2012-05-30
CY1109978T1 (el) 2014-09-10
AR020601A1 (es) 2002-05-22
CA2336743A1 (en) 2000-01-20
NO313834B1 (no) 2002-12-09
EP1093381B1 (en) 2003-08-20
EP2316476B1 (en) 2015-11-25
AU4534099A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
ES2341170T5 (es) Péptidos antigénicos derivados de telomerasa
ES2252933T5 (es) Sistemas de ascensor
ES2181153T5 (es) Compuestos de triazinilaminoestilbeno
DE69930986D1 (de) Hochauflösende Kamera
DE69925393D1 (de) Zweidimensionale Bildaufnahmevorrichtung
DE69515712D1 (de) Hochauflösender Filmabtaster
DE69841107D1 (de) Multispektraler zweidimensionaler bildgebeuder spekteometer
DE69822958D1 (de) Bildaufnahmevorrichtung mit Mitteln zur Erweiterung des Dynamikbereichs
DE69824068D1 (de) Abbildungsgerät
DE69924308D1 (de) Farbbildaufnahmegerät
DE69811669D1 (de) Bildkompression
DE69729916D1 (de) Dynamische bildgrössenänderung
DE69919278D1 (de) Bildprojektionsvorrichtung
DE69803326D1 (de) Negativ arbeitendes Bildaufzeichnungsmaterial
DE69713257D1 (de) Bilderzeugungsvorrichtung
DE69838194D1 (de) Bildaufnahmevorrichtung
DE19700396B4 (de) Bilderzeugungsvorrichtung
DE69718862D1 (de) Multidirektionale Bildaufnahmevorrichtung mit mehreren 3D-Kameras
DE69715175D1 (de) Bilderzeugung
DE69838200D1 (de) Bildlesegerät
DE69701755D1 (de) Bilderzeugungsvorrichtung
NO983828D0 (no) Kontrastmiddel
DE69830137D1 (de) Farbbildaufnahmegerät
DE59602613D1 (de) Transferbilder
DE69812061D1 (de) Bilderzeugungsgerät